PDL BioPharma: Now Is The Time To Buy

PDL BioPharma's (NASDAQ:PDLI) shares are significantly undervalued (I believe this, and so does PDL management). Now is the time to buy. At present, PDLI has $2.45 per share of cash, a 1.74 cash to debt ratio, hidden assets about to be unlocked, and a low valuation, trading at a forward P/E of 13.75. I predict PDLI could increase 50% due to upcoming acquisitions, increasing earnings, share buybacks, and the market's realization of PDLI's current valuation. In short, the market has turned a blind eye to PDL's balance sheet and it doesn't believe in these catalysts propositions because the company had a disappointing 2016.